Member Info for CTSFO

This suggests bolus and prolonged infusions have similar cardio toxicity in the real world.

https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e19123

Evening. I’ve been looking at efficacy and safety of bolus (normal) vs prolonged infusion administration of doxorubicin. The preceding idea being a continuous, prolonged, infusion should be safer than intermittent bolus delivery because the peak plasma levels are minimised.

No evidence of improved efficacy here:

https://www.cancernetwork.com/view/continuous-doxorubicin-does-not-improve-efficacy-in-soft-tissue-sarcoma

A breakdown of all the presentations (oral and poster) last year. 20,000 people attended - in person or online. What matters is presenting here, and then getting the facts out.

https://www.aacr.org/wp-content/uploads/2023/04/AACR2023_AbstractPresentations040123.pdf

And Carling isn’t lager, it’s pish.

Exactly that. HMRC wanted to treat Jaffa Cakes as biscuits and also VAT on them, the producers wanted them to remain cakes and be zero VAT rated.

The producers won!

https://www.astonshaw.co.uk/news/jaffa-cake-tax/

Is a ‘Jaffa Cake’ a cake or a biscuit?

And why does it matter?

Morning Alex, this supports your post. Minimum Effective Dose vs Maximum Tolerated Dose.

https://www.detroitnews.com/story/life/wellness/2024/02/07/cancer-drugs-lowering-doses-side-effects/72502695007/

D-Geeman that explanation nails it! Not happy we won’t be able to ‘bag’ drink drivers… 🚔🚔🚔

Ice, evening. A small correction to your post. Avacta will have written up the trial protocol and had it accepted by the FDA and equivalent regulatory agencies. The actual selection and treatment of patients will be done by Oncologists separated from Avacta. Avacta will be paying Sloan Kettering Memorial, and other cancer centres, but they won’t have direct ‘hands on’ the patients.

This makes the data more reliable and robust.

The nescient life of BELLAMY:

1) Lick a window

2) Chew a crayon

3) Post the Directors haven’t bought many shares

4) Repeat

SERIOUSLY??? THE BoD DIDN’T BUY ANY?????

If only this had been pointed out already!! Oh…

F me, it’s like a 5 year old asking “Are we nearly there yet?”

Evening all.

Fingers crossed we get more data on ‘therapeutically relevant’ tumour cell levels. At present what we’ve been told is close to useless. Plain dox has therapeutically relevant levels achieved within its licensed dose. But it’s only effective in approx 20% of patients at this dose regime. Multi Drug Resistance is such a huge problem for doxorubicin. We need to see TME / tumour cell levels of AVA6000 released doxorubicin that is beating plain doxorubicin hands down. Either through shorter intervals between doses, higher free doxorubicin delivery at dose, or both. It’s difficult to find the rate of AVA6000 separation in presence of FAP in tumours, but one slide does show a massive release of free doxorubicin if AVA6000 is incubated in a FAP environment for 18 hours.

AACR can’t come quickly enough.

GLA

This:

“Well, what do you notice about Avacta’s poster? Oh look AVA6000 isn’t a prodrug anymore it’s a PEPTIDE DRUG CONJUGATE (PDC).

Why? Because prodrug only speaks of a one-off but PDC speaks of a groundbreaking platform.”

🙏👏👏👏👏👌

Morning BV. At least the reply wasn’t

“What’s the MHRA?”

GLA

“ With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit”

Fast growing diagnostics??? So why sell it…

Quick explanation

“Difficult to read” as in I didn’t want to be reading it. The post was spot on.

Rory, please take this as discussion not argument. I read what you posted about early stage Pharma and their valuations. Difficult to read, but it made sense. Yet at the same time there are Broker’s Notes suggesting the sp should be higher than the £1.20 it was at, for example.

The ‘science’ shows great promise. We need a businessman / woman to take this forward. Businesspeople employ scientists, it shouldn’t be the other way around.

“ I still think (more than ever with hindsight), that the "unexpected surprise" of more dosing after Cohort 4 scuppered the cash runway. Why it was a surprise I don't know. Was it the results? I guess it has to be, what else could it be?”

We can safely say Big Al likes a bit of hype… yet still manages to get caught out when the drug performs exactly as it’s meant to. Why TF were they surprised? That’s the bit I don’t get. It does what they wanted it to. Why wasn’t the chance of them getting it right factored in?

Evening BV. All the previous RNSs confirming attendance at AACR have been sent out late March. I think they’ve stated it was a poster being presented.

If Avacta get to give a proper presentation to the main audience, we’re looking good. If all the data out of P1aA1 Q3W - all 7 cohorts - is only worth a little poster, then WTF have they been hiding from us? I know it’s a safety trial, but these really big doses should have biopsy data that confirms significant uptake into the TME / cancer cells.